Healthcare Global Enterprises (HCG) Upgraded to 'Buy' by MarketsMOJO: Strong Growth Potential and Attractive Valuation Make it a Promising Investment Opportunity

Aug 27 2024 06:44 PM IST
share
Share Via
Healthcare Global Enterprises (HCG) has been upgraded to a 'Buy' by MarketsMojo due to its strong long-term growth and positive recent results. The stock is currently in a bullish trend and trading at a discount compared to its historical valuations. However, high debt and slower long-term growth potential may pose risks for investors.
Healthcare Global Enterprises (HCG) Upgraded to 'Buy' by MarketsMOJO: Strong Growth Potential and Attractive Valuation Make it a Promising Investment Opportunity
Healthcare Global Enterprises (HCG) has recently caught the attention of investors as MarketsMOJO has upgraded its stock call to 'Buy' on August 27, 2024. This midcap company in the healthcare services industry has shown strong potential for growth, making it an attractive investment opportunity.
One of the main reasons for the 'Buy' recommendation is the company's healthy long-term growth. HCG has consistently shown an annual growth rate of 31.09% in its operating profit, indicating a strong and stable financial performance. In addition, the company's recent results for June 2024 have been positive, with a 58.7% growth in its PAT(Q) and a highest ever NET SALES(Q) of Rs 525.58 crore. From a technical standpoint, the stock is currently in a bullish range and has shown improvement in its technical trend. Multiple factors such as MACD, Bollinger Band, DOW, and OBV are all indicating a bullish trend for the stock. Moreover, HCG is currently trading at a discount compared to its average historical valuations, making it an attractive buy for investors. In the past year, the stock has generated a return of 15.68%, while its profits have risen by 59.8%. This has resulted in a PEG ratio of 1.9, further solidifying the company's potential for growth. However, there are some risks associated with investing in HCG. The company has a high Debt to EBITDA ratio of 4.09 times, which may affect its ability to service debt. Additionally, its net sales have only grown at an annual rate of 14.13% over the last 5 years, indicating a slower long-term growth potential. Furthermore, HCG has underperformed the market in the last year, generating a return of 15.68% compared to the market's return of 39.59%. This may be a cause for concern for some investors. In conclusion, Healthcare Global Enterprises has shown strong potential for growth and has been upgraded to a 'Buy' by MarketsMOJO. With its healthy financial performance and attractive valuation, it is a promising investment opportunity for those looking to invest in the healthcare services industry. However, investors should also consider the risks associated with the company before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News